1. La Reclasificación Federal del Cannabis.
El presidente Donald Trump firmó una orden ejecutiva que dirige a las agencias federales a acelerar el proceso de reclasificación de la marihuana bajo la Ley de Sustancias Controladas (CSA). Este movimiento saca al cannabis de la Lista I, la categoría más restrictiva reservada para drogas sin uso médico aceptado y alto potencial de abuso (como la heroína), para moverla a una clasificación inferior, generalmente la Lista II.
- President donald trump signed an executive order that could reclassify marijuana as a less dangerous drug, aiming to expand cannabis research.
- President donald trump signed an executive order to reclassify marijuana from a schedule i drug to a schedule ii substance under the controlled substances act.
- Trump reclassifies marijuana to schedule ii in historic shift president donald trump signed an executive order on thursday. This action directs federal agencies to reclassify marijuana.
- The order to place cannabis in the same category as tylenol with codeine would mark the most significant change in us drug policy since 1971.
2. Implicaciones para la Investigación y la Industria.
El principal objetivo de la reclasificación es facilitar la investigación médica sobre el cannabis, un área históricamente obstaculizada por su estatus en la Lista I. Además, el cambio promete un alivio fiscal significativo para las empresas de cannabis que operan legalmente a nivel estatal, al eliminar la aplicación de la Sección 280E del código de impuestos federal.
- The change could help the industry without legalizing the drug.
- Reclassifying marijuana as a schedule ii drug will loosen restrictions on medical researchers, not recreational users.
- The move would make it easier to conduct medical research on the drug, though it stops short of federal.
- Among the most immediate impacts of rescheduling marijuana as a schedule ii drug would be relief from irs code 280e, which prevents businesses that handle schedule i or ii substances from deducting routine expenses such as rent, payroll and equipment.
- President donald trump signed an executive order on december 18, 2025, to reclassify marijuana from a schedule i drug to a schedule ii drug, which allows for more medical research and could reduce tax burdens on the cannabis industry.
3. Limitaciones y Reacciones Políticas.
A pesar de la importancia del cambio, la orden ejecutiva no legaliza el uso recreativo del cannabis a nivel federal. El proceso de reclasificación, aunque acelerado, aún requiere la aprobación final de la DEA. La decisión generó críticas, incluyendo la oposición de algunos republicanos que argumentan que la marihuana debe permanecer en la Lista I, y el escepticismo de quienes temen que el cambio beneficie principalmente a las grandes farmacéuticas o sea una maniobra política.
- The order i am about to sign doesnt legalize marijuana in any way, shape, or form and in no way sanctions its use as a recreational drug.
- Some republicans have spoken out in opposition to any changes and urged mr trump to maintain current standards.
- I dont trust trump at all, and think hes somehow going to let big tobacco or big pharma take over.
- Reclassifying the drug from its status as the most tightly regulated schedule i substance would not legalize or decriminalize cannabis the change will have bigger effects on legal businesses medical research than the average consumer cannabis experts say.
- Rescheduling to schedule ii hands everything to do with cannabis over to big pharma.